Botulinum toxin type A in chronic neuropathic pain in refractory leprosy

Sousa, Emanuel de Jesus Soares de; Sousa, Gustavo Celeira de; Baia, Vitor Ferreira; Somensi, Danusa Neves; Xavier, Marília Brasil

doi:10.1590/0004-282x20190053

Cited by 9 publications

(7 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Ischemia can affect vasodilation and defecation. Furthermore, hypoxia may affect the blood perfusion of specific organs in the abdomen, potentially leading to vascular reperfusion and oxidative stress [ 10 , 11 ] infliction. When the IAH state is relieved, the blood flow of the kidneys increases.…”

Section: Bont-a Injection Improves Iah In Rats Undergoing Abdominal A...mentioning

confidence: 99%

Botulinum Toxin Type A Injection Improves the Intraperitoneal High Pressure in Rats Treated with Abdominal Wall Plasty

Zhang

Shen

Yang

et al. 2022

Computational Intelligence and Neuroscience

View full text Add to dashboard Cite

The aim of the study is mainly to study the subject of BoNT-A injection to improve IAH in rats undergoing abdominal angioplasty. The study problem in surgery, especially in ICU, burn, and trauma centers, intra-abdominal hypertension (IAH), and abdominal compartment syndrome (ACS) are common complications. At present, there are various treatments for IAH. The intramuscular injection of Botulinum toxin type A (BoNT-A) into the abdominal wall has received a lot of attention. Based on this, this study proposes a method for measuring abdominal pressure, applies BoNT-A to reduce abdominal pressure in the IAH state of abdominal wall angioplasty, and explores a way to increase the compliance of the abdominal wall under the premise of maintaining the sealing of the abdominal cavity, so as to realize the expansion of the abdominal cavity. A method is achieved to reduce intra-abdominal pressure and eliminate or alleviate ACS. The results of the experiment showed that when the rats in the control group were injected with the same amount of normal saline as the rats in the experimental group, the IAP was significantly higher than that in the experimental group ( P < 0.05 ). This shows that BoNT-A increases the compliance of the abdominal wall while maintaining the closure of the abdominal cavity, thereby increasing the volume of the abdominal cavity and alleviating the state of IAH in rats.

show abstract

Section: Bont-a Injection Improves Iah In Rats Undergoing Abdominal A...mentioning

confidence: 99%

Botulinum Toxin Type A Injection Improves the Intraperitoneal High Pressure in Rats Treated with Abdominal Wall Plasty

Zhang

Shen

Yang

et al. 2022

Computational Intelligence and Neuroscience

View full text Add to dashboard Cite

show abstract

“…Uma das opções utilizadas atualmente no tratamento da dor crônica nesses pacientes é a toxina botulínica (Sousa et al, 2019).…”

Section: Resultsunclassified

“…Por esse motivo, um estudo realizado por Sousa et al (2019) avaliou a efetividade do uso da toxina botulínica no tratamento da dor crônica em pacientes com hanseníase. Observou-se que a toxina botulínica tipo A foi capaz de reduzir os níveis de dor rapidamente na primeira semana após sua aplicação e permaneceu estável no restante do tempo, o que sugere possíveis mecanismos analgésicos e, além disso, poucos eventos adversos (Sousa et al, 2019).…”

Section: Resultsunclassified

Inovações no tratamento da dor crônica

Souza

Bispo²,

Borges³

2022

RSD

View full text Add to dashboard Cite

Objetivo: A dor crônica ocorre quando há persistência da sensação dolorosa por mais de três meses. Acomete cerca de 30% dos pacientes e é o principal motivo de busca por atendimento médico e uso de fármacos. A terapia medicamentosa é uma importante ferramenta que visa aumentar a qualidade de vida do indivíduo, bem como a não medicamentosa na abordagem multidisciplinar. Assim, este trabalho teve como objetivo avaliar novas opções de tratamento na abordagem da dor crônica. Metodologia: Foi realizada uma revisão bibliográfica através dos descritores “updates”, “management”, “chronic pain” nas seguintes bases de dados: PubMed; Scientific Eletronic Library Online (SCIELO); Literatura Latino Americana e do Caribe em Ciências da Saúde (LILACS), além dos livros “Miller Anestesia” 9a ed e Tratado de Dor Musculoesquelética, da Sociedade Brasileira de Ortopedia e Traumatologia. Resultados e Discussão: Atualmente, existem diversos fármacos disponíveis, sendo os principais: opioides, anti-inflamátorios não esteroides, antidepressivos, antiepiléticos e compostos serotoninérgicos. Os estudos acerca do uso de cannabioides cresceram nos últimos anos, mas ainda não há evidências para o uso dela como tratamento de primeira linha nessa patologia. Opióides são eficazes para dores de origem oncológica, enquanto as derivadas de outros processos fisiopatológicos respondem melhor às outras opções disponíveis, como antidepressivos duais ou antiepiléticos. Ressalta-se a importância de incluir atividade física, psicoterapia e fisioterapia nos casos necessários. Além disso, a toxina botulínica tem ganhado destaque por sua efetividade na intervenção. Conclusão: A dor crônica é uma doença complexa que envolve processos orgânicos e emocionais e necessita de manejos farmacológicos e não farmacológicos.

show abstract

“…Botulinum toxin type A has a beneficial role in the treatment of neuropathic pain [ 41 , 42 , 43 , 44 , 45 , 46 ]. It has both antinociceptive and anti-inflammatory activity, the two mechanisms being dissociated.…”

Section: Discussionmentioning

confidence: 99%

Chronic Facial Pain: Trigeminal Neuralgia, Persistent Idiopathic Facial Pain, and Myofascial Pain Syndrome—An Evidence-Based Narrative Review and Etiological Hypothesis

Gerwin

2020

IJERPH

View full text Add to dashboard Cite

Trigeminal neuralgia (TN), the most common form of severe facial pain, may be confused with an ill-defined persistent idiopathic facial pain (PIFP). Facial pain is reviewed and a detailed discussion of TN and PIFP is presented. A possible cause for PIFP is proposed. (1) Methods: Databases were searched for articles related to facial pain, TN, and PIFP. Relevant articles were selected, and all systematic reviews and meta-analyses were included. (2) Discussion: The lifetime prevalence for TN is approximately 0.3% and for PIFP approximately 0.03%. TN is 15–20 times more common in persons with multiple sclerosis. Most cases of TN are caused by neurovascular compression, but a significant number are secondary to inflammation, tumor or trauma. The cause of PIFP remains unknown. Well-established TN treatment protocols include pharmacotherapy, neurotoxin denervation, peripheral nerve ablation, focused radiation, and microvascular decompression, with high rates of relief and varying degrees of adverse outcomes. No such protocols exist for PIFP. (3) Conclusion: PIFP may be confused with TN, but treatment possibilities differ greatly. Head and neck muscle myofascial pain syndrome is suggested as a possible cause of PIFP, a consideration that could open new approaches to treatment.

show abstract

Botulinum toxin type A in chronic neuropathic pain in refractory leprosy

Cited by 9 publications

References 16 publications

Botulinum Toxin Type A Injection Improves the Intraperitoneal High Pressure in Rats Treated with Abdominal Wall Plasty

Botulinum Toxin Type A Injection Improves the Intraperitoneal High Pressure in Rats Treated with Abdominal Wall Plasty

Inovações no tratamento da dor crônica

Chronic Facial Pain: Trigeminal Neuralgia, Persistent Idiopathic Facial Pain, and Myofascial Pain Syndrome—An Evidence-Based Narrative Review and Etiological Hypothesis

Contact Info

Product

Resources

About